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Abstract
Background: Statin can induce the gene expression of bone morphogenetic protein-2. Red yeast
rice (RYR, Hongqu), i.e. rice fermented with Monascus purpureus, contains a natural form of statin.
This study demonstrates the effects of RYR extract on bone formation.
Methods: Bone defects were created in the parietal bones of two New Zealand white rabbits. In
the test animal, two defects were grafted with collagen matrix mixed with RYR extract. In the
control animal, two defects were grafted with collagen matrix alone. UMR 106 cell line was used
to test RYR extract in vitro. In the control group, cells were cultured for three durations (24 hours,
48 hours and 72 hours) without any intervention. In the RYR group, cells were cultured for the
same durations with various concentrations of RYR extract (0.001 g/ml, 0.005 g/ml and 0.01 g/ml).
Bicinchoninic acid (BCA) assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay and alkaline phosphatase (ALP) assay were performed to measure total protein,
mitochondrial activity and bone cell formation respectively.
Results: The test animal showed more formation of new bone in the defects than the control
animal. RYR significantly increased the optical density in the MTT assay and ALP activity in vitro.
Conclusion: RYR extract stimulated new bone formation in bone defects in vivo and increased
bone cell formation in vitro.
Background
For treating osteoporosis or healing bone defects after
trauma or surgery, it is necessary to find better medicines
to enhance bone formation. Bone morphogenetic pro-
teins (BMPs) are important regulators in osteogenic differ-
entiation during fracture repair [1]. Wang et al. [2]
demonstrated that bone morphogenetic protein-2 (BMP-
2) caused commitment and differentiation of multi-
potential stem cell line into osteoblast-like cells. In an
attempt to discover small molecules that induce BMP-2
gene expression, Mundy et al. [3] tested more than 30 000
compounds and identified that statin was the only com-
pound that specifically increased BMP-2 gene expression.
Statin is known as a cholesterol-lowering agent that inhib-
its hepatic hydroxymethylglutaryl coenzyme A (HMG-
CoA) reductase, the rate-limiting enzyme in the meval-
onate pathway. Our previous study showed that statin
increased local bone formation by 308% in 14 days in an
animal model [4]. Another study indicated that the statin-
mediated activation of BMP-2 promoter was a result of its
ability to inhibit HMG-CoA [5]. These studies suggest that
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HMG-CoA reductase inhibitors may induce BMP-2 gene
expression thereby increasing bone formation.
Red yeast rice (RYR, Hongqu), a Chinese dietary seasoning
prepared by fermenting rice with Monascus purpureus [6]
(Figure 1), has been used in Chinese medicine for centu-
ries. RYR contains monacolins which are a family of
HMG-CoA reductase inhibitors [7]. Moreover, monacolin
K is equivalent to the statin known as mevinolin or lovas-
tatin. Other active ingredients in RYR include sterols (β-
sitosterol, campesterol, stigmasterol, sapogenin), isofla-
vones and monounsaturated fatty acids [8]. RYR extract
may promote bone formation but has not been experi-
mentally demonstrated. The present study investigates the
effects of RYR extract on bone formation in vivo and in
vitro.
Methods
Preparation of RYR extract
RYR was purchased from a local Chinese medicine store
and was identified morphologically and histologically
according to standard Chinese herbal identification pro-
cedures [9]. A voucher specimen including identification
and classification of the plant was preserved in the Hard
Tissue Laboratory, University of Hong Kong. RYR extract
was prepared according to the protocol for injection prep-
aration of traditional Chinese medicine [10]. For every 4
g of RYR powder, 40 ml of HPLC grade water was added
and the mixture was boiled with stirring on a hot plate for
4 hours. HPLC grade water was added occasionally to pre-
vent the mixture from drying. After boiling, the final vol-
ume of the mixture was made up to 4 ml by adding HPLC
grade water. The mixture was cooled to room temperature
and then centrifuged (4648 × g). The supernatant was col-
lected and filtered with a 0.22 μm sterile syringe filter
(25JP020AS, MPS, USA) into a sterile glass bottle. Each ml
of the supernatant contained 1 g of RYR extract.
In vivo qualitative study
The method and animal model used in the present study
have been previously described [4]. Four 10 × 5 mm2 full-
thickness bone defects were created in the parietal bones
of two inbred New Zealand white rabbits. The rabbits
were five months old (adult stage) and weighed between
3.5 kg to 4.0 kg. One of them was used as control while
the other was used as test animal. The animal handling
and experimental protocol was approved by the Commit-
tee on the Use of Live Animals in Teaching and Research,
University of Hong Kong. Two defects of the test animal
were grafted with collagen matrix with RYR extract; two
defects of the control animal were grafted with collagen
matrix alone. The animals were pre-medicated one hour
before surgery with oxytetracycline hydrochloride (200
mg/ml, 30 mg/kg body weight, Tetroxyla, Bimeda, Ire-
land) and buprenorphine hydrochloride (0.3 ml/kg body
weight, Hypnorm, Janssen Pharmaceutical, Belgium),
supplemented with diazepam (5 mg/ml, 1 mg/kg body
weight, Valium 10, Roche). In order to maintain the level
of neuroleptanalgesia, increments of Hypnorm (0.1 ml/
kg) were given at 30-minute intervals during the opera-
tion.
The surgical procedure consisted of the creation of two 10
× 5 mm2 full-thickness (approximately 2 mm) cranial
defects, devoid of periosteum, using templates, in the
parietal bones. The defects were produced with round
stainless steel burs (1 mm in diameter) on a low speed
dental drill. Outlines of the defects were made initially by
making holes of full thickness in the parietal bone with a
stainless steel wire template bent to the required size of
the defect. The holes were joined to complete the process.
During the cutting of the bones, copious amounts of ster-
ile saline were used for irrigation and to minimize thermal
damage to the tissues. In the test animal, the defects were
filled with 0.02 g of purified absorbable fibrillar collagen
matrix (Collagen Matrix, USA) with 0.2 ml of RYR extract
(1 g/ml). The grafts were prepared 15 minutes before
grafting. In the control animal, the defects were grafted
with 0.02 g of the same collagen matrix with 0.2 ml water
for injection.
All wounds were closed with interrupted 3/0 black silk
sutures. No attempt was made to approximate the perios-
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teum to prevent the barrier effect. Postoperatively, the rab-
bits were given oxytetracycline hydrochloride daily for ten
days and buprenorphine hydrochloride daily for two
weeks.
Two weeks after surgery, the animals were sacrificed with
sodium pentobarbitone. Immediately after death, defects
and surrounding tissues were removed for histological
preparation and examination.
Tissues were fixed in 10% buffered formal saline solution,
demineralized with K's Decal Fluid (sodium formate/for-
mic acid) and double embedded in celloidin-paraffin
wax. Serial, 5-μm-thick sections of the whole defect were
cut perpendicular to the long axis. The slides were stained
with Periodic acid-Schiff stain for identification of new
bone formation.
In vitro quantitative study
Cell culture
UMR 106, a rat osteoblastic cell line derived from osteosa-
rcoma, was used as a model system for in vitro studies of
the effect of parathyroid hormone on osteoblasts [11].
UMR 106 cells (ATCC, CRL-1661) were cultured in Dul-
becco's modified Eagle's medium (Gibco, UK) which con-
tained fetal bovine serum (10% vol, Gibco, UK) and
antibiotics penicillin G sodium (100 units/ml, Gibco,
UK) and streptomycin (100 μl/ml, Gibco, UK), and incu-
bated at 37°C in a humidified atmosphere of 5% CO2 and
95% air [12].
In the control group, cells were cultured without interven-
tion for three durations (24 hours, 48 hours and 72
hours). In the RYR group, cells were cultured with RYR
extract of various concentrations (0.001 g/ml, 0.005 g/ml
and 0.01 g/ml) for three durations (24 hours, 48 hours
and 72 hours) in 96-well tissue culture plates (4–5 × 104
cells/well, Corning, USA). Each experiment had eight
samples and was repeated once.
BCA assay for total protein
The total protein is an indicator for the biosynthetic
capacity of bone cell cultures. The bicinchoninic acid
(BCA) assay is a biochemical assay for determining the
total level of protein in a solution using colorimetric tech-
niques [13]. This method combines the reduction of the
Cu2+ to Cu+ by proteins in an alkaline medium with the
highly sensitive and selective colorimetric detection of the
Cu+ using a BCA containing reagent [14]. The purple-
colored reaction product of this assay is a chelation of two
BCA molecules with one Cu+. This water-soluble com-
pound exhibits a strong absorbance at 562 nm and is lin-
early proportional to the protein concentrations over a
broad range (20–2000 μg/ml) [15]. Cells were lysed and
the cellular material was transferred to 250 μl of buffer
(10 mM Tris HCl, pH 7.5, 0.5 mM MgCl2 and 0.1% Tri-
ton-X100). The cellular material was homogenized by two
freeze-and-thaw cycles [15]. The cellular protein concen-
tration was determined by a BCA protein assay kit (Pierce,
USA).
MTT assay for cell viability and mitochondrial activity
The cell viability and mitochondrial activity of the bone
cells after exposure to various concentrations of RYR
extract were determined by the colorimetric MTT assay
which detects the conversion of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, USA)
to a purple formazan product. MTT is a pale yellow tetra-
zolium salt that produces a dark blue formazan product
when incubated with living cells. MTT ring is cleaved in
active mitochondria in living cells [13]. The MTT assay
was used to measure the bone cell viability and mitochon-
drial activities. Cells were incubated with 0.5 mg/ml of
MTT in the final four hours of each interval. The medium
was then decanted; the formazan salt was dissolved in 150
μl of acid-isopropanol; and the optical density was deter-
mined at 570 nm against a reference wavelength of 690
nm with an ELISA reader [13].
ALP assay for osteogenic activity
Alkaline phosphatase (ALP) assay is a standard method to
measure osteogenic activity of bone cells in vitro. The ALP
assay protocol of Declercq et al. [12] was followed. Mono-
layers of cultured cells were rinsed with Ringer solution.
Cells were lysed and the cellular material was transferred
to 250 μl of buffer (10 mM Tris HCl, pH 7.5, 0.5 mM
MgCl2 and 0.1% Triton X-100). The cellular material was
homogenized by two freeze-and-thaw cycles. The ALP
assay was performed using p-nitrophenylphosphate as
substrate. Each sample (50 μl) was added to 50 μl of p-
nitrophenylphosphate (4.34 mM) in buffer (100 mM gly-
cine, pH 10.3, 1 mM MgCl2). The mixture was incubated
at 37°C for 30 minutes on a bench shaker. The enzymatic
reaction was stopped by adding 50 μl of 1 M NaOH. The
reaction product was quantified by absorbance measure-
ment at 405 nm against p-nitrophenol (PNP) standards.
The ALP activity is expressed as mM PNP/μg protein.
Statistical analysis
Data were analyzed with software SPSS 15.0 for Windows
(SPSS, USA). Normality test (Kolmogorov-Smirnov test, P
> 0.05) was performed. The unpaired t-tests with Bonfer-
roni correction (P = 0.05) were used to compare the con-
trol with various concentrations of RYR extract (0.001
mm, 0.005 mm and 0.01 mm). The results with P < 0.05
were considered to be statistically significant.Chinese Medicine 2008, 3:4 http://www.cmjournal.org/content/3/1/4
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Results
In vivo qualitative study
All animals remained in excellent health throughout the
course of the experiment and recovered rapidly after oper-
ation. There was no evidence of side effects or infection in
any of the animals.
In the rabbit grafted with RYR extract in collagen matrix,
new bone was formed at the host bone/graft interface
tended to grow across the defect (Figure 2). Integration of
the RYR extract and collagen with the recipient bed was
characterized by the appearance of new bone. No cartilage
was found. At higher magnification, new bone could be
seen growing around a collagen matrix fragment and
tended to growth towards and amalgamate with the colla-
gen matrix. The presence of bone cells indicated that new
bone was formed.
In the control animal, little new bone was formed at the
host bone/graft interface. Some collagen fibers were
present at the center of the defects (Figure 3). In both rab-
bits, the defect was healed, with fibrous tissue bridging
across the defect.
In vitro quantitative study
BCA assay
RYR extract at all the tested concentrations did not show
any statistically significant effect on total protein.
MTT assay
RYR extract increased the optical density of the purple for-
mazan product in the MTT assay. The effect was most con-
sistent at 48 hours where the increase ranged from 60% to
74%. At 24 hours, only RYR extracts of 0.001 g/ml and
0.005 g/ml showed statistically significant effects. At 72
hours, only RYR extract of 0.001 g/ml showed a statisti-
cally significant effect. RYR extract of 0.01 g/ml showed a
statistical significant effect at 24 hours but not at 72 hours
(Table 1).
ALP assay
RYR extract increased ALP activity in all groups. RYR
extract of 0.005 g/ml significantly increased ALP activity at
48 hours and 72 hours. RYR extract of 0.001 g/ml signifi-
cantly increased ALP activity only at 48 hours. RYR extract
of 0.01 g/ml significant increased ALP activity ranging
from 16% to 31% in all three time durations (Table 2).
Discussion
In comparison with the control, treatment of bone defects
with RYR extract was demonstrated in vivo to have
enhanced new bone formation. Treatment of UMR 106
osteosarcoma cells with RYR extract was found to have
increased cell viability and mitochondrial activity as
measured by the MTT assay and higher osteogenic activity
as detected by the ALP assay. The effect of RYR extract on
new bone formation might not be non-specific (e.g. gen-
eral biosynthetic activities in the cells) because no
increased total protein was detected. It is to be confirmed
Photomicrograph of bone defect grafted with collagen matrix  alone (control) on day 14 Figure 3
Photomicrograph of bone defect grafted with colla-
gen matrix alone (control) on day 14. No new bone 
was observed across the defect. There was new bone near 
the ends of the host bone (H). Collagen matrix (C) remained 
across the bone defect (Periodic acid-Schiff stain, original 
magnification ×40).
Photomicrograph of bone defect grafted collagen matrix  mixed with RYR extract (test) on day 14 Figure 2
Photomicrograph of bone defect grafted collagen 
matrix mixed with RYR extract (test) on day 14. New 
bone (N) was observed across the defect. H = Host bone. 
Some collagen matrix (C) remained at the center of the bony 
defect (Periodic acid-Schiff stain, original magnification ×40).Chinese Medicine 2008, 3:4 http://www.cmjournal.org/content/3/1/4
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whether the statin-like substances in RYR extract are the
main osteogenic agents in RYR extract. The specific mech-
anism of the RYR osteogenic agents is also to be investi-
gated.
A previous study indicated a temporal expression pattern
of different markers during the osteoblast development
[16]. Different markers (e.g. ALP and osteopontin)
showed an increase and then decrease in expression dur-
ing different stages. It is possible that the MTT response
varies during the osteoblast development. As UMR 106
cells express ALP in their basal state [17], only potent oste-
ogenic agents can significantly increase ALP activity in
UMR 106 cells.
The results suggest that the effect of RYR extract may be
dose-dependent and that a drop of the ALP activity at 48
hours and 72 hours may be a result of an increase in cel-
lular proliferation offsetting an increase in ALP activity.
RYR extract contains several statin-like components that
inhibit the HMG-CoA reductase. Statin-mediated activa-
tion of BMP-2 promoter was inhibited by mevalonate
which is the downstream metabolite of HMG-CoA reduct-
ase [5]. The effect of RYR extract on bone formation sug-
gests that the inhibition of HMG-CoA reductase in the
mevalonate pathway may increase bone cells. Further
studies on this pathway and its relation to bone formation
may help reveal some of the RYR's biochemical actions
and potential uses in treating bone defects and osteoporo-
sis.
Conclusion
RYR extract stimulated new bone formation in bone
defects in vivo and significantly increased bone cell forma-
tion in vitro. RYR is a natural product with potential in
treating bone defects and probably also osteoporosis.
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Table 2: ALP assay of UMR106 cells
Concentration of RYR extract (g/ml) Control 0.001 0.005 0.01
PNP (0 hour) mean (SD) 8.26 (0.95) - - -
PNP (24 hours) mean (SD) 8.14 (0.53) 7.50 (2.39) 7.07 (1.54) 9.74 (1.37)
P-value* NS NS 0.039
PNP (48 hours) mean (SD) 5.58 (0.57) 6.62 (0.84) 6.40 (0.50) 6.46 (0.64)
P-value* 0.033 0.024 0.033
PNP (72 hours) mean (SD) 4.50 (0.32) 3.89 (0.80) 5.17 (0.42) 5.81 (0.87)
P-value* NS 0.010 0.012
* Unpaired t-tests with Bonferroni correction were performed to compare the control with samples of various RYR extract concentrations.
PNP: mM p-nitrophenol (PNP) per μg protein of RYR extract
NS: Not statistically significant
Table 1: MTT assay of UMR 106 cells
Concentration of RYR extract (g/ml) Control 0.001 0.005 0.01
Optical density (0 hour) mean (SD) 0.196 (0.019) - - -
Optical density (24 hours) mean (SD) 0.218 (0.052) 0.287 (0.018) 0.342 (0.033) 0.257 (0.040)
P-value* 0.021 < 0.001 NS
Optical density (48 hours) mean (SD) 0.177 (0.031) 0.282 (0.048) 0.293 (0.014) 0.306 (0.044)
P-value* < 0.001 < 0.001 < 0.001
Optical density (72 hours) mean (SD) 0.360 (0.049) 0.421 (0.035) 0.360 (0.014) 0.372 (0.031)
P-value* 0.036 NS NS
* Unpaired t-tests with Bonferroni correction were performed to compare with the control of various RYR extract concentrations.
Optical density: optical density of the purple formazan product at 570 nm
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